This, together with our finding that trpy is mostly expressed in the Drosophila brain starting at the adult stage and that feeding flies hyperforin is effective, suggests that hyperforin may be a useful candidate therapeutic drug to test in clinical trials for the treatment of neurodevelopmental disorders associated with disruptive mutations in TRPC6. The gene discussed is TRPC6; the disease is neurodevelopmental disorder.